| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 784.51 | 8.3% | 11.7% |
| Total Income | 784.51 | 8.3% | 11.7% |
| Expenditure | 714.17 | 16.5% | 16.4% |
| PBT | -5.22 | 110.1% | 133.8% |
| Net Profit | 2.37 | 89.4% | 1581.3% |
| OPM | 8.97% | 6.40pp | 3.67pp |
| NPM | 0.30% | 2.79pp | 0.32pp |
| EPS | 0.01 | 85.7% |
Amneal Reports Q3 2025 Net Revenue of $785M, Up 12% YoY
04 May 2026 · 4 May, 8:27 am
Summary
Amneal Pharmaceuticals reported a strong third quarter in 2025, with net revenue reaching $785 million, a 12% increase year-over-year. Net income improved to $2 million, compared to a net loss in the same quarter of the previous year. Adjusted EBITDA saw a slight increase of 1%, reaching $160 million. The company updated its full-year 2025 guidance, projecting net revenue between $3.0 billion and $3.1 billion, and adjusted EBITDA between $675 million and $685 million.
Key Highlights
- 1
Amneal's net revenue for Q3 2025 reached $785 million, reflecting a 12% increase compared to $702 million in Q3 2024.
- 2
The company reported a net income of $2 million in Q3 2025, a significant improvement from the net loss of $0.2 million in Q3 2024.
- 3
Adjusted EBITDA for Q3 2025 was $160 million, a 1% increase compared to Q3 2024.
- 4
Diluted income per share in Q3 2025 was $0.01, compared to a diluted loss per share of $0.00 in Q3 2024.
- 5
Adjusted diluted earnings per share in Q3 2025 increased by 6% to $0.17, compared to $0.16 in Q3 2024.
- 6
The company updated its 2025 full-year guidance, projecting net revenue between $3.0 billion and $3.1 billion.
- 7
AvKARE net revenue increased 24% driven by growth in the government label sales channel.
Management Comments
Chirag and Chintu Patel
“Amneal delivered another strong quarter and updated our 2025 outlook, underscoring the strength of our diversified business and the ongoing evolution of our portfolio. CREXONT® for Parkinson’s disease and other key branded products continue to drive Specialty growth, complemented by the launch this month of BREKIYA® in the migraine space. At the same time, our Affordable Medicines segment is entering a significant new product launch cycle, with multiple complex approvals this quarter and numerous new key launches expected ahead. Together with our recent refinancing, Amneal is closing 2025 and entering 2026 from a position of strength and momentum.”
Informational and educational content only. Not investment advice.